Table 4

Odds ratios for postmenopausal breast cancer by genotypes in the vitamin D receptor gene according to ER and PR status of the tumour

Genotype

ER-positive tumours
ER-negative tumours
PR-positive tumours
PR-negative tumours

n (controls)
n (cases)
OR (95% CI)
n (cases)
OR (95% CI)
n (cases)
OR (95% CI)
n (cases)
OR (95% CI)

TaqI









     TT
980
337
1
121
1
297
1
159
1
     Tt/tt
1,629
653
1.18 (1.00–1.38)
186
0.88 (0.69–1.13)
547
1.10 (0.93–1.30)
293
1.11 (0.89–1.37)
FokI









     FF
998
394
1
127
1
331
1
190
1
     Ff/ff
1,598
586
0.95 (0.81–1.10)
177
0.86 (0.67–1.10)
505
0.96 (0.82–1.14)
257
0.84 (0.68–1.03)
VDR-5132









     CC
892
347
1
113
1
298
1
162
1
     CT/TT
1,715
640
0.99 (0.84–1.16)
194
0.92 (0.71–1.18)
543
0.97 (0.82–1.15)
290
0.97 (0.78–1.20)
Cdx2









     GG
1,701
641
1
190
1
546
1
283
1
     GA/AA
905
351
1.01 (0.86–1.17)
118
1.14 (0.88–1.46)
301
1.01 (0.86–1.20)
169
1.11 (0.90–1.38)

We conducted a conditional logistic regression stratified by year of birth adjusted for age at menopause, first-degree family history of breast cancer, history of benign breast disease, number of pregnancies (≥28th week), age at menarche, breastfeeding history, total number of mammograms, use of hormone therapy, body mass index, education level and smoking status. Data on oestrogen receptor (ER) and progesterone receptor (PR) status was available for 1,302 and 1,301 cases, respectively.

Abbas et al. Breast Cancer Research 2008 10:R31   doi:10.1186/bcr1994